全文获取类型
收费全文 | 2737篇 |
免费 | 135篇 |
国内免费 | 17篇 |
专业分类
耳鼻咽喉 | 50篇 |
儿科学 | 40篇 |
妇产科学 | 39篇 |
基础医学 | 317篇 |
口腔科学 | 38篇 |
临床医学 | 197篇 |
内科学 | 830篇 |
皮肤病学 | 118篇 |
神经病学 | 243篇 |
特种医学 | 53篇 |
外国民族医学 | 25篇 |
外科学 | 245篇 |
综合类 | 4篇 |
一般理论 | 1篇 |
预防医学 | 294篇 |
眼科学 | 13篇 |
药学 | 163篇 |
中国医学 | 10篇 |
肿瘤学 | 209篇 |
出版年
2023年 | 22篇 |
2022年 | 43篇 |
2021年 | 103篇 |
2020年 | 63篇 |
2019年 | 95篇 |
2018年 | 102篇 |
2017年 | 52篇 |
2016年 | 71篇 |
2015年 | 56篇 |
2014年 | 122篇 |
2013年 | 166篇 |
2012年 | 197篇 |
2011年 | 244篇 |
2010年 | 134篇 |
2009年 | 96篇 |
2008年 | 175篇 |
2007年 | 157篇 |
2006年 | 159篇 |
2005年 | 160篇 |
2004年 | 129篇 |
2003年 | 131篇 |
2002年 | 106篇 |
2001年 | 28篇 |
2000年 | 32篇 |
1999年 | 28篇 |
1998年 | 18篇 |
1997年 | 19篇 |
1996年 | 17篇 |
1995年 | 8篇 |
1994年 | 8篇 |
1993年 | 6篇 |
1992年 | 14篇 |
1991年 | 13篇 |
1990年 | 6篇 |
1989年 | 6篇 |
1988年 | 9篇 |
1987年 | 7篇 |
1986年 | 8篇 |
1985年 | 11篇 |
1984年 | 13篇 |
1983年 | 7篇 |
1982年 | 8篇 |
1981年 | 4篇 |
1979年 | 6篇 |
1978年 | 4篇 |
1972年 | 3篇 |
1971年 | 4篇 |
1970年 | 2篇 |
1968年 | 3篇 |
1967年 | 2篇 |
排序方式: 共有2889条查询结果,搜索用时 15 毫秒
131.
Francisco Torres-Bondia Farida Dakterzada Leonardo Galvn Miquel Buti Gaston Besanson Eric Grill Roman Buil Jordi de Batlle Gerard Piol-Ripoll 《The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)》2022,25(4):261
BackgroundBenzodiazepines (BZDs) and Z-drugs (BZDRs) are among the most prescribed medications for anxiety and insomnia, especially among older adults. Our objective was to investigate the association between the use of BZDRs and the risk of dementia.MethodsA community-based retrospective cohort study was conducted based on the data available from 2002 to 2015 in Catalan Health Service. This cohort included all BZDR users (N = 83 138) and nonusers (N = 84 652) older than 45 years. A minimum 5-year lag window and an adjustment for psychiatric problems were applied for the data analysis.ResultsThe hazard ratio (HR) for the risk of incident dementia among BZDR users was 1.22 (95% CI = 1.15 to 1.31). This risk was not significant after adjusting the data confounding factors (HR = 1.01; 95% CI = 0.94 to 1.08). We observed a higher risk with short-to-intermediate half-life BZDs (HR = 1.11; 95% CI = 1.04 to 1.20) and Z-drugs (HR = 1.20; 95% CI = 1.07 to 1.33) than for intermediate-to-long half-life BZDs (HR = 1.01; 95% CI = 0.94 to 1.08). We demonstrated a higher risk of incident dementia (HR = 1.23; 95% CI = 1.07 to 1.41 and odds ratio = 1.38; 95% CI = 1.27 to 1.50, respectively) in patients who received 91 to 180 defined daily doses (DDDs) and >180 DDDs compared with patients who received <90 DDD. Regarding patient sex, the risk of dementia was higher in women than in men.ConclusionWe found that the incidence of dementia was not higher among all BZDR users. Short half-life BZDs and Z-drugs increased the risk of dementia at the highest doses, especially in female patients, showing a dose-response relationship. 相似文献
132.
Danese S Sans M de la Motte C Graziani C West G Phillips MH Pola R Rutella S Willis J Gasbarrini A Fiocchi C 《Gastroenterology》2006,130(7):2060-2073
BACKGROUND & AIMS: Angiogenesis is a critical component of neoplastic and chronic inflammatory disorders, but whether angiogenesis also occurs in inflammatory bowel disease (IBD) has yet to be established. We assessed mucosal vascularization, expression of endothelial alphaVbeta3 integrin, angiogenic factors, and their bioactivity in Crohn's disease (CD) and ulcerative colitis (UC) mucosa. METHODS: Mucosal endothelium was immunostained for CD31 and factor VIII and quantified by digital morphometry. alphaVbeta3 expression was studied in vivo by confocal microscopy and in vitro by flow cytometric analysis of human intestinal microvascular endothelial cells (HIMECs). Vascular endothelial growth factor (VEGF), interleukin (IL)-8, and bFGF levels were measured in mucosal extracts and cells and angiogenic bioactivity shown by induction of HIMEC migration and the corneal and chorioallantoic membrane angiogenesis assays. RESULTS: Microvessel density was increased in IBD mucosa. Endothelial alphaVbeta3 was strongly expressed in IBD but only sporadically in normal mucosa and was up-regulated in HIMECs by VEGF, tumor necrosis factor alpha, and bFGF. IBD mucosal extracts induced a significantly higher degree of HIMEC migration than control mucosa, and this response was mostly dependent on IL-8 and less on basic fibroblast growth factor or vascular endothelial growth factor. Compared with normal mucosa, IBD mucosal extracts induced a potent angiogenic response in both the corneal and chorioallantoic membrane assays. CONCLUSIONS: These results provide morphological, phenotypic and functional evidence of potent angiogenic activity in both CD and UC mucosa, indicating that the local microvasculature undergoes an intense process of inflammation-dependent angiogenesis. Thus, angiogenesis appears to be an integral component of IBD pathogenesis, providing the practical and conceptual framework for anti-angiogenic therapies in IBD. 相似文献
133.
Raquel Almodovar Juan C. Torre Alonso Enrique Batlle Concepción Castillo Eduardo Collantes-Estevez Eugenio de Miguel Senén González Jordi Gratacós Azucena Hernández Xavier Juanola Luis F. Linares Manuel J. Moreno Mireia Moreno Victoria Navarro-Compán Carlos Rodríguez Lozano Jesus Sanz Agustí Sellas Estíbaliz Loza Pedro Zarco 《Reumatología clinica》2018,14(3):155-159
Objective
To standardize clinical evaluation of patients with axial spondyloarthritis (SpA) and psoriatic arthritis (PsA) using a checklist.Methods
Qualitative study that included: 1) nominal group (18 experts); 2) literature reviews of measures used in the assessment of patients with axial SpA or PsA; and 3) focus groups, one with rheumatologists and another with patients, organized to become familiar with their opinion on medical assistance. Taking this into account, the experts selected the measures to be included in the checklist based on their relevance, feasibility, and the outcome type.Results
The checklist includes measures for the evaluation of personal history, physical examination, activity and function, laboratory tests, imaging studies and treatments. It also defines risk factors of radiographic progression, predictors of the response to biological therapies, and comprises measures of excellence.Conclusions
This checklist for patients with axial SpA and PsA could help standardize daily clinical practice and improve clinical management and patient prognosis. 相似文献134.
Gabriele Di Sante Timothy G. Pestell Mathew C. Casimiro Sara Bisetto Michael J. Powell Michael P. Lisanti Carlos Cordon-Cardo Mireia Castillo-Martin Dennis M. Bonal Valentina Debattisti Ke Chen Liping Wang Xiaohong He Michael W. McBurney Richard G. Pestell 《The American journal of pathology》2015,185(1):266-279
135.
Esther Sapiña-Beltrán Gerard Torres Montserrat Martínez-Alonso Manuel Sánchez-de-la-Torre Maria Franch Carmen Bravo Juan F. Masa Miquel Felez Ana Maria Fortuna-Gutierrez Jorge Abad Francisco García-Río Luciano F. Drager Ronald Lee Chi-Hang Miguel Ángel Martínez-García Ferran Barbé Mireia Dalmases 《Archivos de bronconeumologia》2018,54(10):518-523
Introduction
Patients with resistant hypertension (RH) have a high risk of developing cardiovascular events; therefore, new therapeutic approaches to better control blood pressure may be useful in improving cardiovascular outcomes. The prevalence of obstructive sleep apnea (OSA) is very high among patients with RH. Continuous positive airway pressure (CPAP) has been shown to be an effective treatment for reducing blood pressure in patients with RH. Nevertheless, the long-term effect of CPAP treatment on cardiovascular outcomes has not been explored.The main objective of the SARAH study is to assess the impact of OSA and its treatment on cardiovascular outcomes (morbidity and mortality) in patients with RH.Methods
This study is a multi-center, prospective, observational cohort study. A total of 1371 patients with RH will be enrolled in the study and followed once a year for five years. At inclusion, ambulatory blood pressure monitoring (ABPM) and a sleep study will be performed in all subjects. Socio-demographic, clinical and cardiovascular variables will be collected at baseline and follow-up. Subsequently, subjects with OSA will be managed according to local standard practice. Based on the OSA diagnosis and its treatment, three cohorts of subjects with RH will be defined: non-OSA, treated OSA and non-treated OSA.Conclusions
This study will contribute to elucidating the long-term impact of OSA treatments on blood pressure control and cardiovascular outcomes in patients with RH. These results will contribute to improve the cardiovascular prognosis of patients with RH. 相似文献136.
Diagnosis and treatment of latent tuberculosis infection in liver transplant recipients in an endemic area 总被引:2,自引:0,他引:2
Benito N Sued O Moreno A Horcajada JP González J Navasa M Rimola A 《Transplantation》2002,74(10):1381-1386
BACKGROUND: Treatment of latent tuberculosis infection (LTBI) with isoniazid is recommended for transplant recipients with positive tuberculin skin test (TST). However, TST could be an imperfect identifier of LTBI in this population. In addition, the risk of isoniazid hepatotoxicity could be high in liver transplant recipients (LTR). A retrospective cohort study was performed to evaluate the diagnosis and treatment of LTBI in LTR. METHODS: Charts of all 547 patients who received primary liver transplantation at a University Hospital in Spain between 1988 and 1998 were reviewed. RESULTS: TST was performed in 373 patients (71%) before transplantation. The result was positive in 89 (24%). The median follow-up after transplantation was 49 months. None of the TST-positive patients developed tuberculosis (TB), but 5 out of 284 patients with negative TST (1.76%) had active TB (P=0.6). Twenty-three patients received isoniazid as treatment of LTBI according to the decision of the attending physician. None of these patients developed TB, but 4 of them (17%) presented isoniazid hepatotoxicity. Among patients who did not receive isoniazid, 2 out of 21 (9.52%) with radiologic previous TB developed active TB versus 0.44% (2/452) among the remaining patients (relative risk [RR], 27.8, 95% CI, 3.2-147). CONCLUSIONS: Treatment of LTBI with isoniazid can not be recommended to LTR on the basis of a positive TST because it is an imperfect identifier of patients at risk of TB. LTR with radiologic features of previous TB are at higher risk of posttransplant active TB. Isoniazid-related hepatotoxicity is more frequent among LTR than in the general population. 相似文献
137.
138.
139.
MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation 总被引:7,自引:0,他引:7
Burrel M Llovet JM Ayuso C Iglesias C Sala M Miquel R Caralt T Ayuso JR Solé M Sanchez M Brú C Bruix J;Barcelona Clínic Liver Cancer Group 《Hepatology (Baltimore, Md.)》2003,38(4):1034-1042
Helical computerized tomography (CT) and magnetic resonance imaging (MRI) are used for staging of hepatocellular carcinoma (HCC) prior to curative treatments but underestimate tumor extension in 30% to 50% of cases when compared with pathologic explants. This study compares a new technology, MRI angiography (MRA), with triphasic helical CT in detection of HCC. Fifty cirrhotic patients, 29 with HCC, undergoing liver transplantation were analyzed. MRA was performed with a 3-D breath-hold fast spoiled gradient-echo sequence by using an effective section thickness of 2 to 2.5 mm. The gold standard was the pathologic examination (liver cut into 5-mm slices). One hundred twenty-seven lesions were identified at the explant: 76 HCC, 13 high-grade dysplastic nodules, 31 macroregenerative nodules, 7 hemangiomas. Diameter of the main HCC nodules was 29 +/- 14 mm and 11 +/- 7 mm for the 47 additional nodules. On a per nodule basis, sensitivity of MRA was superior to CT (58/76 [76%] vs. 43/70 [61%], respectively, P =.001). Sensitivity of MRA for detection of additional nodules decreased with size (>20 mm: 6/6 [100%]; 10-20 mm: 16/19 [84%]; <10 mm: 7/22 [32%]) and was superior to CT for nodules 10 to 20 mm (84% vs. 47%, P =.016). Nonspecific hypervascular nodules >5 mm at MRA were HCC in two thirds of the cases. In conclusion, MRA has a high diagnostic accuracy for HCC > or =10 mm and is more sensitive than triphasic helical CT in nodules sized 10 to 20 mm. MRA is the optimal technique for HCC staging prior to curative therapies. 相似文献
140.
D'Haens GR Panaccione R Higgins PD Vermeire S Gassull M Chowers Y Hanauer SB Herfarth H Hommes DW Kamm M Löfberg R Quary A Sands B Sood A Watermeyer G Watermayer G Lashner B Lémann M Plevy S Reinisch W Schreiber S Siegel C Targan S Watanabe M Feagan B Sandborn WJ Colombel JF Travis S 《The American journal of gastroenterology》2011,106(2):199-212; quiz 213
The advent of biological therapy has revolutionized inflammatory bowel disease (IBD) care. Nonetheless, not all patients require biological therapy. Selection of patients depends on clinical characteristics, previous response to other medical therapy, and comorbid conditions. Availability, reimbursement guidelines, and patient preferences guide the choice of first-line biological therapy for luminal Crohn's disease (CD). Infliximab (IFX) has the most extensive clinical trial data, but other biological agents (adalimumab (ADA), certolizumab pegol (CZP), and natalizumab (NAT)) appear to have similar benefits in CD. Steroid-refractory, steroid-dependent, or complex fistulizing CD are indications for starting biological therapy, after surgical drainage of any sepsis. For fistulizing CD, the efficacy of IFX for inducing fistula closure is best documented. Unique risks of NAT account for its labeling as a second-line biological agent in some countries. Patients who respond to induction therapy benefit from systematic re-treatment. The combination of IFX with azathioprine is better than monotherapy for induction of remission and mucosal healing up to 1 year in patients who are na?ve to both agents. Whether this applies to other agents remains unknown. IFX is also effective for treatment-refractory, moderate, or severely active ulcerative colitis. Patients who have a diminished or loss of response to anti-tumor necrosis factor (TNF) therapy may respond to dose adjustment of the same agent or switching to another agent. Careful consideration should be given to the reasons for loss of response. There are insufficient data to make recommendations on when to stop anti-TNF therapy. Preliminary evidence suggests that a substantial proportion of patients in clinical remission for >1 year, without signs of active inflammation can remain in remission after stopping treatment. 相似文献